Indivior PLC stock (GB00BYZ0C031): Upward EPS estimate revisions signal growth

Analyst estimates for Indivior PLC's 2026 earnings per share have risen from $3.03 to $3.35 over the past 60 days, reflecting optimism in the pharmaceutical sector amid recent 6-K filing.

Indivior PLC, a specialty pharmaceutical company focused on addiction treatment, has seen positive momentum in analyst forecasts. Over the past 60 days, estimates for its 2026 earnings per share increased from $3.03 to $3.35, according to Zacks via TradingView as of May 2026. This upward revision highlights growing confidence in the company's pipeline and market position. Additionally, Indivior filed a 6-K with the SEC on January 2, 2025, as reported by GuruFocus as of Jan 02, 2025, which may relate to ongoing regulatory or operational updates relevant to US investors tracking Nasdaq-listed INDV.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Indivior PLC
• Sector/industry: Pharmaceuticals / Addiction Treatment
• Headquarters/country: United Kingdom
• Core markets: US, Europe
• Key revenue drivers: SUBLOXONE, PERSERIS
• Home exchange/listing venue: Nasdaq (INDV)
• Trading currency: USD

Indivior PLC: core business model

Indivior PLC develops and markets medications for opioid use disorder and related addictions. Its lead product, SUBLOXONE sublingual film, dominates the US market for buprenorphine-based treatments, generating the bulk of revenue. The company reported its products treated over 5 million patients globally in recent years, with a strong emphasis on the US where opioid addiction remains a public health crisis. Indivior's business model centers on innovation in delivery systems to improve patient compliance and deter abuse.

Listed on Nasdaq under ticker INDV, Indivior provides US investors exposure to the growing addiction treatment sector, valued at billions amid ongoing demand. The firm's focus on evidence-based therapies positions it within healthcare policies that prioritize substance abuse solutions.

Main revenue and product drivers for Indivior PLC

SUBLOXONE accounts for the majority of sales, with US net revenue figures from Q4 2024 filings showing sustained demand despite generic competition. PERSERIS, an extended-release risperidone injection for schizophrenia, represents growth potential in mental health adjacencies. According to company reports published in early 2025, these products drove revenue stability. Indivior's pipeline includes OPNT003 for cocaine intoxication, advancing through clinical stages.

For US investors, Indivior's Nasdaq listing and heavy US revenue reliance (over 90% from North America per recent annual reports) tie its performance to domestic healthcare spending and regulatory environments like FDA approvals.

Industry trends and competitive position

The addiction treatment market is expanding due to the US opioid epidemic, with projections from sector analysts estimating growth to $7 billion by 2028. Indivior competes with generics but differentiates via abuse-deterrent formulations. Its market share in buprenorphine remains robust, supported by patents and partnerships.

Why Indivior PLC matters for US investors

With primary listing on Nasdaq and majority revenue from the US, Indivior offers direct exposure to American healthcare dynamics. Its products address a critical need in the opioid crisis, aligning with federal initiatives like the SUPPORT Act, influencing long-term demand.

Conclusion

Indivior PLC continues to navigate a competitive pharmaceutical landscape with strong analyst estimate upgrades for 2026 EPS and recent SEC filings underscoring operational transparency. US investors monitor its addiction treatment leadership amid sector growth. Developments in pipeline assets and market share will shape future performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.